TLDR;
This video analyzes CVS Health stock, considering its diverse business segments, recent financial performance, and future prospects. Despite headwinds and a less attractive outlook, the stock is currently trading at a discount, making it a potentially attractive but risky investment. The analysis uses a discounted cash flow valuation model to determine a fair value for the stock, concluding that it is undervalued but requires a high tolerance for risk due to ongoing challenges in the healthcare industry.
- CVS Health has a diverse business including physical locations, insurance, and pharmaceuticals.
- The stock is trading at a discount compared to the S&P 500 average.
- The recommendation is to consider CVS Health stock as a buy, but with caution due to the risks involved.
Introduction [0:00]
The video addresses whether CVS Health stock is a buying opportunity given the current challenges and policy impacts on healthcare affordability. Despite ongoing efforts to improve healthcare affordability, which could negatively impact CVS, the video aims to determine if the stock's market price presents a worthwhile investment.
CVS Health's Business and Financial Performance [0:35]
CVS Health has a diverse business with physical locations, an insurance business, and a pharmaceutical side. In 2025, the company reported $402 billion in revenue, a 7.8% increase from the previous year. While analysts predict a slowdown in revenue growth, forecasts still project an increase to $443 billion by 2028, despite the expected reduction in physical locations due to changing consumer behavior.
Profitability and Cash Flow [1:41]
CVS has historically had low profitability, and recent challenges have further reduced margins. The operating cash flow to sales ratio was just 2.6% in the most recent 12-month period, a slight increase from 2.4% the year before. This is down from a peak of 6.3% in 2021 during the pandemic when demand for testing and related medicines was high. Given the current situation, the author would not want to pay a premium for this business.
Stock Valuation and Fair Value [2:28]
CVS stock is trading at a discount, with a forward price to earnings ratio of 10.23 and a forward price to operating cash flow of just 9.5. This is less than half the average valuation of stocks in the S&P 500. The author's discounted cash flow valuation model estimates the fair value of CVS Health at $92 per share, compared to its current market price of $73.
Opportunities and Challenges [3:12]
CVS has an opportunity to leverage its physical locations as a competitive advantage, similar to Walmart and Target. Despite modest top-line growth expectations, management could increase profits through efficiencies. The company is projected to generate $8 billion in free cash flow in 2026, growing to $12 billion by 2028.
Investment Recommendation [4:29]
The primary reason to consider CVS Health stock is its attractive valuation, despite unexciting revenue growth prospects and ongoing pressures from the current administration on healthcare companies. The stock is rated as a buy, but it is a risky investment due to persistent headwinds. This investment is suitable only for those who can tolerate the risk of a potential value trap.
Additional Resources [5:52]
Access to the author's spreadsheet containing discounted cash flow valuations for over 200 companies is available by joining the channel at the investor tier or above. This resource helps determine a good price to pay for a stock.
